Monday, June 13

9:00 - 9:30am PST
Fireside chat with John Carroll
10:30 - 11:25am PST
Cell therapy 2.0: The new frontier confronts new safety threats

Tuesday, June 14

6:00 - 7:00am PST
Breakfast & Networking
7:00 - 7:25am PST
Fireside chat with John Carroll
7:30 - 8:30am PST
Managing a biotech in turbulent times
9:30 - 10:25am PST
Decentralized trials

Wednesday, June 15

9:00 - 9:30am PST
Fireside chat with Zachary Brennan
9:45 - 10:25am PST
The new drug marketers
11:00 - 11:55am PST
The future of gene editing
12:00pm - 12:30pm PST
Fireside chat with John Carroll
MON - JUNE 13
9:00 - 9:30am PST
Virtual

Fireside Chat with John Carroll

John Carroll
John Carroll
Editor & Founder
Endpoints News
10:30 - 11:25am PST
Virtual

Cell therapy 2.0: The new frontier confronts new safety threats

sponsored by Catalent

The first generation of cell therapy developers had to face their own special challenge: cytokine release storm. But now that that hurdle has largely been cleared, the next wave of cell therapies in the clinic are running smack dab into a whole new set of safety issues that have triggered an array of clinical holds in the field. Just what is going wrong here and what can scientists do to get past this threat?

sponsored by Catalent
John Carroll
John Carroll
Editor & Founder
Endpoints News
moderator
TUE - JUNE 14
6:00 - 7:00am PST
Live

Breakfast & Networking

sponsored by Catalent

Proof of vaccination required. Mask requirements will follow local mandates.

7:00 - 7:25am PST
Live
Livestream

Fireside Chat with John Carroll

sponsored by Bayer
Sebastian Guth
Sebastian Guth
President of Pharmaceuticals, Americas Region
Bayer
John Carroll
John Carroll
Editor & Founder
Endpoints News
7:30 - 8:30am PST
Live
Livestream

Managing a biotech in turbulent times

sponsored by FujiFilm Diosynth

The money tree on Wall Street has withered badly for biotech this year. After a long running boom, generalists are out of here — for now — leaving high risk, high reward plays like biotech high and dry. So it’s time for more careful planning, and that can mean prioritizing the pipeline, looking at cutting the fat without touching the bone and muscle and generally doing a lot better job of managing the burn rate as you steer to a galaxy of catalysts. And we have some of the industry’s top advisors on hand to provide some insights, as well as answer your questions.

sponsored by FujiFilm Diosynth
Faheem Hasnain
Faheem Hasnain
Co-Founder, Chairman, President & CEO
Gossamer Bio
Andrew Lo
Andrew Lo
Professor, Director of the Laboratory for Financial Engineering
MIT Sloan School of Management
Kristina Burrow
Kristina Burrow
Managing Director
Arch Venture Partners
Neil Kumar
Neil Kumar
Founder, CEO, Director
BridgeBio
Paul Hastings
Paul Hastings
CEO
Nkarta
John Carroll
John Carroll
Editor & Founder
Endpoints News
moderator
9:30 - 10:25am PST
Virtual

Decentralized trials

sponsored by Catalent

Getting more patients — as well as a more diverse group — to participate in clinical trials has been a hot topic for years now, and some proponents have been urging regulators to modernize how drug developers are allowed to conduct clinical trials. Endpoints News regulatory expert Zachary Brennan will gather a panel of experts together to examine just how this should be done. This is a must-watch panel for anyone interested in drug development.

sponsored by Catalent
Ronan Brown
Ronan Brown
Senior VP and Head of Patient Centric Solutions & Decentralized Trials
IQVIA
Craig Lipset
Craig Lipset
Advisor and Founder
Clinical Innovation Partners
Zachary Brennan
Zachary Brennan
Senior Editor
Endpoints News
moderator
WED - JUNE 15
9:00 - 9:30am PST
Virtual

Fireside Chat with Zachary Brennan

sponsored by Catalent
Zachary Brennan
Zachary Brennan
Senior Editor
Endpoints News
9:45 - 10:45am PST
Virtual

The new drug marketers

Senior editor Beth Snyder Bulik is bringing together some of the top execs from biotechs that have made the big leap from development to marketing their own drugs. What does it take to compete with the big established players in pharma? And what are the most common pitfalls in making the transition? If you’re considering a first-time launch – or just curious about how they did it – you won’t want to miss this one.

Vlad Coric
Vlad Coric
CEO and Chairman of the Board
Biohaven
Rebecca McLeod
Rebecca McLeod
US General Manager
Argenx
Max Colao
Max Colao
Chief Commercial Officer
Aurinia Pharmaceuticals
Patricia Torr
Patricia Torr
President and General Manager
Idorsia Pharmaceuticals US
Beth Snyder Bulik
Beth Snyder Bulik
Senior Editor
Endpoints News
moderator
11:00 - 11:55am PST
Virtual

The future of gene editing

sponsored by Metagenomi

Now that the CRISPR revolution has taken hold, academic scientists and biotechs are expanding the notion of what’s possible with new tools to edit the genome. Bayer, Moderna, Vertex, and other industry leaders have declared the field as a key driver for their future pipelines. We’ll be taking an in-depth look with Metagenomi's CEO and co-founder, Brian C. Thomas, and other thought leaders in the space at how to forge a path for safe and efficacious gene editing therapeutics and the future of enabling technologies that will make this possible. Furthermore, we will focus on the financial and business endeavors that will ultimately make way for breakthroughs in gene editing to benefit patients.

sponsored by Metagenomi
Brian Thomas
Brian Thomas
CEO and Founder
Metagenomi
Jürgen Eckhardt
Jürgen Eckhardt
Head
Leaps by Bayer
Will Dere
Will Dere
Vice Dean Research
School of Medicine at University of Utah Health Sciences Center
John Carroll
John Carroll
Editor & Founder
Endpoints News
moderator
12:00 - 12:30pm PST
Virtual

Fireside Chat with John Carroll

sponsored by Catalent
John Carroll
John Carroll
Editor & Founder
Endpoints News